AVTX (Avalo Therapeutics) Total Liabilities: $31.57 Mil (As of Mar. 2026)


AVTX Avalo Therapeutics Inc AVTX
23 GF Score
Price $18.16
GF Value $0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avalo Therapeutics Total Liabilities?

Avalo Therapeutics AVTX +1.11% 23 Total Liabilities is $31.57 Mil as of Mar. 2026. GuruFocus rates AVTX with a GF Score™ of 23/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Avalo Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $31.57 Mil.

Avalo Therapeutics's quarterly Total Liabilities declined from Sep. 2025 ($33.55 Mil) to Dec. 2025 ($33.41 Mil) and declined from Dec. 2025 ($33.41 Mil) to Mar. 2026 ($31.57 Mil).

Avalo Therapeutics's annual Total Liabilities increased from Dec. 2023 ($13.69 Mil) to Dec. 2024 ($17.70 Mil) and increased from Dec. 2024 ($17.70 Mil) to Dec. 2025 ($33.41 Mil).

Avalo Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Avalo Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics Total Liabilities Chart

Avalo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.13 44.28 13.69 17.70 33.41

Avalo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.91 22.01 33.55 33.41 31.57
AVTX
23GF Score
Avalo Therapeutics Inc AVTX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalo Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Avalo Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.94+(0+20.035
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.434+0+0)
=33.41

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=116.458-83.049
=33.41

Avalo Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.599+(0+19.52
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.446+0+0)
=31.57

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=99.885-68.32
=31.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $31.57 Mil mean?
Avalo Therapeutics (AVTX) has a Total Liabilities of $31.57 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Avalo Therapeutics and its competitors.
Is Avalo Therapeutics' Total Liabilities too high?
Avalo Therapeutics' current Total Liabilities is $31.57 Mil. Overall, Avalo Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' Total Liabilities compare to EVMN and TBPH?
Avalo Therapeutics' Total Liabilities of $31.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Avalo Therapeutics and its competitors. Avalo Therapeutics's current Total Liabilities is $31.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $18.16 — trading 60433.3% above its estimated fair value. The current Total Liabilities is $31.57 Mil. Avalo Therapeutics' overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current Total Liabilities is $31.57 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avalo Therapeutics (AVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of $18.16 is trading 60433.3% above its estimated GF Value™ of $0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for AVTX:

  • Total Liabilities: $31.57 Mil
  • GF Value™: $0.03 vs. price of $18.16 (60433.3% above fair value)
  • GF Score™: 23/100 with 5 warning signs

No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avalo Therapeutics Business Description

Other Exchanges C6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
23GF Score

Get the complete analysis for AVTX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.16
Price
$0.03
GF Value